ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 93 filers reported holding ORIC PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $268,462 | +500.2% | 37,972 | +1067.3% | 0.00% | – |
| Q1 2024 | $44,729 | +49.5% | 3,253 | 0.0% | 0.00% | – |
| Q4 2023 | $29,928 | +52.1% | 3,253 | 0.0% | 0.00% | – |
| Q3 2023 | $19,681 | -32.4% | 3,253 | -13.3% | 0.00% | – |
| Q2 2023 | $29,131 | +164.8% | 3,754 | +48.4% | 0.00% | – |
| Q2 2022 | $11,000 | -78.4% | 2,530 | -73.7% | 0.00% | – |
| Q1 2022 | $51,000 | -64.1% | 9,606 | 0.0% | 0.00% | – |
| Q4 2021 | $142,000 | -24.9% | 9,606 | +6.2% | 0.00% | – |
| Q3 2021 | $189,000 | +155.4% | 9,046 | +117.6% | 0.00% | – |
| Q2 2021 | $74,000 | -32.7% | 4,157 | -7.7% | 0.00% | – |
| Q1 2021 | $110,000 | 0.0% | 4,502 | +38.9% | 0.00% | – |
| Q4 2020 | $110,000 | +307.4% | 3,242 | +202.4% | 0.00% | – |
| Q3 2020 | $27,000 | -42.6% | 1,072 | -24.1% | 0.00% | – |
| Q2 2020 | $47,000 | – | 1,412 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 602,272 | $4,673,631 | 14.75% |
| Nextech Invest Ltd. | 4,285,714 | $33,257,141 | 11.30% |
| Column Group LLC | 3,568,181 | $27,689,085 | 10.75% |
| Prosight Management, LP | 5,522,936 | $42,857,984 | 6.42% |
| Invus Financial Advisors, LLC | 1,007,575 | $7,818,782 | 4.18% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,450,822 | $11,258,379 | 3.48% |
| VR Adviser, LLC | 2,142,856 | $16,628,563 | 2.66% |
| Euclidean Capital LLC | 747,550 | $5,800,988 | 1.49% |
| Frazier Life Sciences Management, L.P. | 2,142,855 | $16,628,555 | 0.99% |
| Monaco Asset Management SAM | 378,222 | $2,935,003 | 0.82% |